WO1990008159A1 - Method for removing dna from protein preparations - Google Patents

Method for removing dna from protein preparations Download PDF

Info

Publication number
WO1990008159A1
WO1990008159A1 PCT/US1990/000409 US9000409W WO9008159A1 WO 1990008159 A1 WO1990008159 A1 WO 1990008159A1 US 9000409 W US9000409 W US 9000409W WO 9008159 A1 WO9008159 A1 WO 9008159A1
Authority
WO
WIPO (PCT)
Prior art keywords
incubating
protein
dna
done
resin
Prior art date
Application number
PCT/US1990/000409
Other languages
French (fr)
Inventor
George D. J. Green
Christopher P. Prior
Original Assignee
Invitron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invitron Corporation filed Critical Invitron Corporation
Publication of WO1990008159A1 publication Critical patent/WO1990008159A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes

Definitions

  • the present invention relates generally to a method for removing DNA from protein preparations. More particularly, the present invention relates to the use of anion exchange resins to reduce the amount of DNA in injectables to levels considered safe.
  • Injectable protein preparations such as mono ⁇ clonal antibodies, pharmaceuticals, vaccines and other compositions, should be rid of substantial amounts of DNA prior to their use. DNA contamination in such prepara ⁇ tions can deleteriously affect the subject to whom they are administered. For instance, unwanted DNA segments might become incorporated into the recipient's genome. The FDA recommends that DNA levels in these preparations be 10 picograms per dose or less.
  • DNA is thus strongly acidic. Because of this property, DNA will bind positively charged groups. Additionally, when pH values are increased, more efficient binding can be effected. Proteins are also negatively charged above their isoelectric point and thus bind posi ⁇ tively charged groups at high pH values. However, salt concentrations can be adjusted so that only minimal amounts of protein will bind these groups at elevated pH values. Thus, a delicate balance must be struck in order to achieve maximum DNA removal from a protein solution without the concomitant loss of significant amounts of protein.
  • the present invention is based on the discovery that the prolonged contact of protein preparations with anion exchange resins, under suitable conditions, can re ⁇ move significant amounts of DNA while rendering acceptable protein yields.
  • a commercially acceptable protein preparation can be produced for use in humans and animals.
  • the present invention is directed to a method for removing DNA from a protein prep ⁇ aration wherein the protein preparation is incubated with an anion exchange resin for a period of time and under conditions sufficient to result in a final protein product containing less than 5 picograms of DNA per milligram of product.
  • a method for removing DNA from a protein preparation comprising incubating the preparation with an anion exchange resin under conditions such that DNA from the protein preparation becomes bound to the resin while substantial amounts of protein from the pro ⁇ tein preparation do not bind the resin.
  • the anion exchange resin comprises a secondary or quaternary anion exchange resin and incubation is car ⁇ ried out at a pH greater than 7, the pH preferably being other than the isoelectric pH of the desired protein. Salt concentrations are kept below about 500mM and incuba ⁇ tion proceeds for more than about 2 hours. Further embodiments of the present invention will occur to those of ordinary skill in the art.
  • Protein preparation refers to any composition, solution or formulation, regardless of purity, that con- tains one or more peptides, polypeptides or proteins. Such a preparation may contain significant amounts of other non-protein substances.
  • Exemplary protein prepara ⁇ tions include but are not limited to polyclonal and mono ⁇ clonal antibody-containing compositions, antigens, drugs, diagnostics, vaccines, injectables, pharmaceutical com ⁇ pounds and other therapeutic agents.
  • the “isoelectric pH” of a protein is the pH at which the protein exhibits no net electric charge and does not move in an electric field.
  • the isoelectric pH of many proteins is known or can be readily determined by methods well known in the art.
  • substantially DNA-free product is one that contains picogram quantities or less of DNA per mg of product.
  • a substantially DNA-free product will contain less than about 50 picograms per mg of prod- uct, more preferably, less than about 20 picograms per mg of product, and most preferably, less than about 10 pico- ' grams per mg of product.
  • anion exchange resin comprises a matrix, such as agarose, cellulose, dextran, silica, and other synthetic polymers, to which secondary, tertiary or quaternary amine groups can be covalently bound. These exchangers are commercially available from several sup ⁇ pliers.
  • Representative anion exchange resins include but are not limited to diethylaminoethyl (DEAE)-substituted materials such as DEAE-substituted cellulose, agarose, or dextran; or quaternary ammonium substituted resins such as Q-Sepharose and QAE-Sephadex, all of which are available from Pharmacia.
  • the instant invention yields a substantially DNA-free protein preparation, suitable for injectable use, DNA levels can be reduced to picogram amounts or less using the following procedure.
  • a protein-containing prep ⁇ aration at any stage of purity is incubated with an anion exchange resin.
  • Suitable resins include secondary and quaternary amine substituted resins with the quaternary amine resins being preferred. Particularly useful is Q Sepharose Fast Flow (Pharmacia) . This resin is a strong anion exchanger with a cross-linked agarose matrix and is stable over a wide range of pH values.
  • the amount of resin used per mg of protein prep- aration need only be an amount that provides sufficient binding sites for the DNA present in the preparation. Amounts on the order of 1 ml resin per mg of product, more usually 1 ml resin per 10-20 mg product, will find use with the present invention. Other suitable ratios are readily determinable by one of ordinary skill in the art.
  • a protein preparation containing a desired pro ⁇ tein is incubated with the resin using a batch process. In this way, the preparation is allowed to remain in con ⁇ tact with the resin for an extended period of time, thus maximizing DNA removal by adsorption of the DNA to the anion exchanger. Incubation should proceed for at least 2 hours, more preferably 4-24 hours or more. When secondary amine anion exchange resins are used, long ⁇ er incubation periods may be necessary in order to effect maximum DNA removal. Such extended incubation favors greater binding due to the slow kinetics of adsorption demonstrated by DNA.
  • incubation should be carried out at high pH values and low salt concentrations, such that the desired protein will remain free from the resin and not become denatured.
  • the capacity of the anion exchangers used in the present invention to bind DNA increases with increas ⁇ ing pH.
  • proteins will have a tendency to bind to the resin at high pH values.
  • Salt concentrations can be adjusted so that only minimal amounts of protein will bind the resin.
  • high salt concentrations can cause proteins to precipitate, resulting in low product yields. Thus, a balance must be struck between the pH levels and salt concentrations used in the instant method.
  • incubation will be carried out at the highest possible pH and the lowest possible salt con- " centration that will effect maximum DNA binding and mini ⁇ mum protein binding.
  • pH values greater than 6, more preferably between 7 and 9, and most preferably 8.0 to 8.5 achieve the desired results.
  • Suit ⁇ able buffers include standard running buffers such as Tris or phosphate, with a salt concentration of less than 500mM. It is thus apparent that the combination of pro- longed exposure, pH values and salt concentrations all contribute to the effectiveness of the instant invention.
  • DNA levels in the product can be determined using any standard assay.
  • Particularly use ⁇ ful is a DNA probe hybridization assay. Such an assay is commercially available as a kit from Oncor (Maryland) and is sensitive to 2-5 picograms of DNA.
  • probes are made from DNA purified from individual cell lines from which the product is de ⁇ rived.
  • DNA from any source is suitable so long as it is cross-reactive with the DNA from the protein preparation.
  • DNA can be isolated from such cells by phe ⁇ nol extraction or other procedures well known in the art. See r e.g., Maniatis, Fritsch & Sambrook, MOLECULAR CLON ⁇ ING: A LABORATORY MANUAL (1982); the series, METHODS IN ENZYMOLOGY (S. Colowick and N. Kaplan eds., Academic
  • the isolated DNA is then biotin-labeled and hybridization and detection performed according to the manufacturer's directions.
  • the isolated DNA is also used to prepare standards.
  • the sample can be compared to these standards in order to determine the amount of DNA present.
  • This process yields protein preparations with DNA concen- trations at or lower to the sensitivity limits of the above described assay.
  • the resulting product con ⁇ tains less than 2-5 picograms of DNA.
  • Such low DNA levels are commercially desirable and render the preparation use- ful as an injectable grade protein.
  • DNA was purified from this cell line using standard procedures.
  • the DNA was biotin-labeled using the Oncor (Maryland) non- isotopic system for DNA probe labeling according to the manufacturer's directions, with the exception that the probe purification step was left out.
  • Biotin labeling, using this system is accomplished by incorporating biotin modified nucleotides into the DNA molecules using a stan ⁇ dard nick translation technique. Samples to be assayed were diluted 1:1 in a 4.5M urea solution, pH 13.0.
  • DNA standards were made by diluting known quan- tities of isolated DNA in the urea buffer described above. The standards were assayed as described above. The pre- treated purified immunoglobulin sample was compared with the standards and found to contain 200-500 picograms of DNA per milligram of purified protein.
  • the purified urine immunoglobulin was then batched with Q Sepharose Fast Flow (Pharmacia) , a quater ⁇ nary ammonium-substituted cross-linked agarose, at a ratio of 20mg of immunoglobulin per ml of resin.
  • Q Sepharose Fast Flow Pharmacia
  • a 20mM Tris buffer was used containing 90mM NaCl, pH 8.0. Incubation proceeded for 2 hours, 4 hours, or overnight.
  • the DNA concentration in the treated protein preparations was de ⁇ termined as described above. DNA was reduced at least 100-fold in all three cases, to 2-5 picograms DNA per mg of product or lower. DNA amounts were at the level of sensitivity of the hybridization assay. Protein loss was between 5-10%. Thus, this treatment yielded a protein preparation suitable for human or animal use.
  • bound DNA can be eluted from the anion exchange resin using a 1M NaCl wash followed by a .1M NaOH wash.
  • the DNA can be assayed and quantified as described above.
  • protein concentrations of the pre- and post-treated prepa ⁇ ration can be determined via UV absorption, the Lowry or Biuret methods, or any other well known assay, and the values compared to determine the percent of protein loss.
  • C.2. A purified murine immunoglobulin. Subclass IgG 2b , derived from Invitron cell line 8B, was assayed-to determine the amount of DNA present in the preparation prior to treatment with the anion exchanger as in example C.l.
  • the sample contained 50-200 picograms of DNA per milligram of purified protein. This product was batched with Q Sepharose Fast Flow at a ratio of 15mg immunoglobu ⁇ lin per ml of resin as described above except that 20mM phosphate, 200mM NaCl, pH 8.5 was used as buffer. In each case, the process reduced DNA greater than 10-fold, to undetectable levels, when assayed as described in example C.l.

Abstract

A method for removing DNA from protein preparations is disclosed. A purified or partially purified protein preparation is incubated with a secondary or quaternary amine anion exchanger for an extended period of time, at high pH values and low salt concentrations, to yield a product suitable for human or animal use.

Description

METHOD FOR REMOVING DNA FROM PROTEIN PREPARATIONS
Technical Field
The present invention relates generally to a method for removing DNA from protein preparations. More particularly, the present invention relates to the use of anion exchange resins to reduce the amount of DNA in injectables to levels considered safe.
Background of the Invention
Injectable protein preparations such as mono¬ clonal antibodies, pharmaceuticals, vaccines and other compositions, should be rid of substantial amounts of DNA prior to their use. DNA contamination in such prepara¬ tions can deleteriously affect the subject to whom they are administered. For instance, unwanted DNA segments might become incorporated into the recipient's genome. The FDA recommends that DNA levels in these preparations be 10 picograms per dose or less.
Previous methods of protein purification gener¬ ally effect the gross removal of DNA early in the purifi¬ cation scheme. Many of these processes do not achieve the low DNA levels required for injectable grade proteins.
Furthermore, column chromatography and other commonly used protein purification techniques often fail to remove maxi¬ mal amounts of DNA due to its slow kinetics of adsorption. The electric charge present on proteins in solu- tion is known to be a function of several parameters in¬ cluding pH and ionic strength. The pH at which a protein has no net electric charge -is its isoelectric pH. The isoelectric pH varies from protein to protein.
The phosphate groups of DNA are fully ionized at any pH above 4. DNA is thus strongly acidic. Because of this property, DNA will bind positively charged groups. Additionally, when pH values are increased, more efficient binding can be effected. Proteins are also negatively charged above their isoelectric point and thus bind posi¬ tively charged groups at high pH values. However, salt concentrations can be adjusted so that only minimal amounts of protein will bind these groups at elevated pH values. Thus, a delicate balance must be struck in order to achieve maximum DNA removal from a protein solution without the concomitant loss of significant amounts of protein.
Summary of the Invention
The present invention is based on the discovery that the prolonged contact of protein preparations with anion exchange resins, under suitable conditions, can re¬ move significant amounts of DNA while rendering acceptable protein yields. Thus, a commercially acceptable protein preparation can be produced for use in humans and animals. In one embodiment, the present invention is directed to a method for removing DNA from a protein prep¬ aration wherein the protein preparation is incubated with an anion exchange resin for a period of time and under conditions sufficient to result in a final protein product containing less than 5 picograms of DNA per milligram of product.
In another embodiment of the instant invention, a method for removing DNA from a protein preparation is provided, the method comprising incubating the preparation with an anion exchange resin under conditions such that DNA from the protein preparation becomes bound to the resin while substantial amounts of protein from the pro¬ tein preparation do not bind the resin.
In several preferred embodiments of the subject invention, the anion exchange resin comprises a secondary or quaternary anion exchange resin and incubation is car¬ ried out at a pH greater than 7, the pH preferably being other than the isoelectric pH of the desired protein. Salt concentrations are kept below about 500mM and incuba¬ tion proceeds for more than about 2 hours. Further embodiments of the present invention will occur to those of ordinary skill in the art.
Detailed Description A. Definitions In describing the present invention, the follow¬ ing terms will be employed, and are intended to be defined as indicated below.
"Protein preparation" refers to any composition, solution or formulation, regardless of purity, that con- tains one or more peptides, polypeptides or proteins. Such a preparation may contain significant amounts of other non-protein substances. Exemplary protein prepara¬ tions include but are not limited to polyclonal and mono¬ clonal antibody-containing compositions, antigens, drugs, diagnostics, vaccines, injectables, pharmaceutical com¬ pounds and other therapeutic agents.
The "isoelectric pH" of a protein is the pH at which the protein exhibits no net electric charge and does not move in an electric field. The isoelectric pH of many proteins is known or can be readily determined by methods well known in the art.
By "substantial amounts of protein" remaining unbound to an exchange resin as contemplated by the in¬ stant invention, is meant that at least 50%, preferably 75% and more preferably 80% or more of the desired protein does not become bound to the exchanger. A "substantially DNA-free" product is one that contains picogram quantities or less of DNA per mg of product. Preferably, a substantially DNA-free product will contain less than about 50 picograms per mg of prod- uct, more preferably, less than about 20 picograms per mg of product, and most preferably, less than about 10 pico- ' grams per mg of product.
An "anion exchange resin" comprises a matrix, such as agarose, cellulose, dextran, silica, and other synthetic polymers, to which secondary, tertiary or quaternary amine groups can be covalently bound. These exchangers are commercially available from several sup¬ pliers. Representative anion exchange resins include but are not limited to diethylaminoethyl (DEAE)-substituted materials such as DEAE-substituted cellulose, agarose, or dextran; or quaternary ammonium substituted resins such as Q-Sepharose and QAE-Sephadex, all of which are available from Pharmacia.
The substituent groups of anion exchangers are positively charged in solution, the degree of ionization being dependent on the pH. Hence, negatively charged mol¬ ecules will adsorb to these exchange resins. DEAE-substi¬ tuted materials are only partially ionized in normal oper¬ ating buffers around pH 6-9, whereas quaternary ammonium groups remain ionized even at pH 12. Scopes, R.K. , Pro¬ tein Purification Principles and Practice, 2d. edition (Springer-Verlag 1987). This is in part due to the higher positive charge density present on the quaternary amine groups as opposed to secondary amines. Thus, quaternary amine anion exchangers are potentially more efficient at binding the negatively charged phosphate groups of DNA.
B. General Method
The instant invention yields a substantially DNA-free protein preparation, suitable for injectable use, DNA levels can be reduced to picogram amounts or less using the following procedure. A protein-containing prep¬ aration at any stage of purity is incubated with an anion exchange resin. Suitable resins include secondary and quaternary amine substituted resins with the quaternary amine resins being preferred. Particularly useful is Q Sepharose Fast Flow (Pharmacia) . This resin is a strong anion exchanger with a cross-linked agarose matrix and is stable over a wide range of pH values.
The amount of resin used per mg of protein prep- aration need only be an amount that provides sufficient binding sites for the DNA present in the preparation. Amounts on the order of 1 ml resin per mg of product, more usually 1 ml resin per 10-20 mg product, will find use with the present invention. Other suitable ratios are readily determinable by one of ordinary skill in the art. A protein preparation containing a desired pro¬ tein is incubated with the resin using a batch process. In this way, the preparation is allowed to remain in con¬ tact with the resin for an extended period of time, thus maximizing DNA removal by adsorption of the DNA to the anion exchanger. Incubation should proceed for at least 2 hours, more preferably 4-24 hours or more. When secondary amine anion exchange resins are used, long¬ er incubation periods may be necessary in order to effect maximum DNA removal. Such extended incubation favors greater binding due to the slow kinetics of adsorption demonstrated by DNA.
In order to maximize DNA removal and minimize protein loss, incubation should be carried out at high pH values and low salt concentrations, such that the desired protein will remain free from the resin and not become denatured. The capacity of the anion exchangers used in the present invention to bind DNA increases with increas¬ ing pH. Similarly, proteins will have a tendency to bind to the resin at high pH values. Salt concentrations can be adjusted so that only minimal amounts of protein will bind the resin. However, high salt concentrations can cause proteins to precipitate, resulting in low product yields. Thus, a balance must be struck between the pH levels and salt concentrations used in the instant method. Preferably, incubation will be carried out at the highest possible pH and the lowest possible salt con- " centration that will effect maximum DNA binding and mini¬ mum protein binding. These parameters will vary according to the specific protein in question. Generally, pH values greater than 6, more preferably between 7 and 9, and most preferably 8.0 to 8.5, achieve the desired results. Suit¬ able buffers include standard running buffers such as Tris or phosphate, with a salt concentration of less than 500mM. It is thus apparent that the combination of pro- longed exposure, pH values and salt concentrations all contribute to the effectiveness of the instant invention. After incubation, DNA levels in the product can be determined using any standard assay. Particularly use¬ ful is a DNA probe hybridization assay. Such an assay is commercially available as a kit from Oncor (Maryland) and is sensitive to 2-5 picograms of DNA.
Generally, probes are made from DNA purified from individual cell lines from which the product is de¬ rived. However, DNA from any source is suitable so long as it is cross-reactive with the DNA from the protein preparation. DNA can be isolated from such cells by phe¬ nol extraction or other procedures well known in the art. See r e.g., Maniatis, Fritsch & Sambrook, MOLECULAR CLON¬ ING: A LABORATORY MANUAL (1982); the series, METHODS IN ENZYMOLOGY (S. Colowick and N. Kaplan eds., Academic
Press, "Inc.) The isolated DNA is then biotin-labeled and hybridization and detection performed according to the manufacturer's directions. The isolated DNA is also used to prepare standards. The sample can be compared to these standards in order to determine the amount of DNA present. This process yields protein preparations with DNA concen- trations at or lower to the sensitivity limits of the above described assay. Thus, the resulting product con¬ tains less than 2-5 picograms of DNA. Such low DNA levels are commercially desirable and render the preparation use- ful as an injectable grade protein.
C. Examples C.l. A purified murine immunoglobulin, derived from Invitron cell line 5F, was assayed to determine the amount of DNA present in the preparation prior to treatment with the anion exchanger via the following method. DNA was purified from this cell line using standard procedures. The DNA was biotin-labeled using the Oncor (Maryland) non- isotopic system for DNA probe labeling according to the manufacturer's directions, with the exception that the probe purification step was left out. Biotin labeling, using this system, is accomplished by incorporating biotin modified nucleotides into the DNA molecules using a stan¬ dard nick translation technique. Samples to be assayed were diluted 1:1 in a 4.5M urea solution, pH 13.0. Subsequent 1:10 dilutions were made in the same buffer. The diluted samples were trans¬ ferred to a hybridization membrane and hybridization and detection performed using the Oncor non-isotopic system according to the manufacturer's directions. Briefly, this system utilizes streptavidin to bind the biotin-labeled DNA. Unbound streptavidin is removed and biotin-labeled alkaline phosphatase added to bind remaining available sites. Hybridized DNA is detected by incubation with 5-Bromo-4-Chloro-3-Indolyl Phosphate and Nitro Blue Tetra- zolium which react in the presence of DNA to produce a blue-colored band. The intensity of the band varies with the amount of DNA present.
DNA standards were made by diluting known quan- tities of isolated DNA in the urea buffer described above. The standards were assayed as described above. The pre- treated purified immunoglobulin sample was compared with the standards and found to contain 200-500 picograms of DNA per milligram of purified protein.
The purified urine immunoglobulin was then batched with Q Sepharose Fast Flow (Pharmacia) , a quater¬ nary ammonium-substituted cross-linked agarose, at a ratio of 20mg of immunoglobulin per ml of resin. A 20mM Tris buffer was used containing 90mM NaCl, pH 8.0. Incubation proceeded for 2 hours, 4 hours, or overnight. The DNA concentration in the treated protein preparations was de¬ termined as described above. DNA was reduced at least 100-fold in all three cases, to 2-5 picograms DNA per mg of product or lower. DNA amounts were at the level of sensitivity of the hybridization assay. Protein loss was between 5-10%. Thus, this treatment yielded a protein preparation suitable for human or animal use.
To test whether this method was effective in removing DNA during earlier stages in the purification process, partially purified murine immunoglobulin was treated as above. After the DNA removal step, the purifi¬ cation process was resumed. The final product was tested for DNA and had no detectable DNA using the hybridization method described. Thus, use of this invention during purification proved as efficacious as treatment of the final purified protein product.
To confirm the amount of DNA removed from the protein preparation using the foregoing method, bound DNA can be eluted from the anion exchange resin using a 1M NaCl wash followed by a .1M NaOH wash. The DNA can be assayed and quantified as described above. Similarly protein concentrations of the pre- and post-treated prepa¬ ration can be determined via UV absorption, the Lowry or Biuret methods, or any other well known assay, and the values compared to determine the percent of protein loss. C.2. A purified murine immunoglobulin. Subclass IgG2b, derived from Invitron cell line 8B, was assayed-to determine the amount of DNA present in the preparation prior to treatment with the anion exchanger as in example C.l. The sample contained 50-200 picograms of DNA per milligram of purified protein. This product was batched with Q Sepharose Fast Flow at a ratio of 15mg immunoglobu¬ lin per ml of resin as described above except that 20mM phosphate, 200mM NaCl, pH 8.5 was used as buffer. In each case, the process reduced DNA greater than 10-fold, to undetectable levels, when assayed as described in example C.l.
The experiment was repeated using only partially purified murine immunoglobulin as described in example C.l. Again, the method proved to be as effective when used during the purification process as it was when used after protein purification.
While the present invention has been illustrated above by certain specific embodiments, it is not intended that these specific examples limit the scope of the inven¬ tion as described in the appended claims.

Claims

wiiaτ; is claimed is:
1. A method for removing DNA from a protein prepa¬ ration comprising incubating said protein preparation with an anion exchange resin, said incubating being done for a period of time and under conditions sufficient to result - in a final protein product containing less than about 5 picograms of DNA per milligram of product.
2. The method of claim 1 wherein said anion ex¬ change resin is selected from the group consisting of sec¬ ondary and quaternary anion exchange resins.
3. The method of claim 2 wherein said incubating is done at a pH greater than about 6.
4. The method of claim 2 wherein said incubating is done at a pH between approximately 7 and 9.
5. The method of claim 4 wherein said incubating is done at a pH other than the isoelectric pH of a protein of interest within said protein preparation.
6. The method of claim 2 wherein said incubating is done at a salt concentration of less than about 500mM.
7. The method of claim 2 wherein said incubating is done for more than about 2 hours.
8. The method of claim 2 wherein said incubating is done for more than about 4 hours.
9. A method for removing DNA from a protein prepa¬ ration comprising incubating said protein preparation with a quaternary amine anion exchange resin for more than about 2 hours, said incubating being done at a pH greater than about 6 and a salt concentration of less than about - 500mM, said incubating resulting in a final protein prod¬ uct containing less than 5 picograms of DNA per milligram of product.
10. A method for removing DNA from a protein prepa¬ ration comprising incubating said protein preparation with an anion exchange resin, said incubating being done under conditions such that DNA from said protein preparation binds to said resin and substantial amounts of protein from said protein preparation do not bind to said resin, said incubation resulting in a final protein product sub¬ stantially free of DNA.
11. The method of claim 10 wherein said incubating results in a final protein product containing less than 5 picograms of DNA per milligram of product.
12. The method of claim 10 wherein said anion ex- change resin is selected from the group consisting of sec¬ ondary and quaternary anion exchange resins.
13. The method of claim 12 wherein said incubating is done at a pH greater than about 6.
14. The method of claim 12 wherein said incubating is done at a pH between approximately 7 and 9.
15. The method of claim 14 wherein said incubating is done at a pH other than the isoelectric pH of a protein of interest within said protein preparation.
16. The method of claim 12 wherein said incubating is done at a salt concentration of less than 500mM.
17. The method of claim 12 wherein said incubating is done for more than about 2 hours.
18. The method of claim 11 wherein said incubating is done for more than about 4 hours.
PCT/US1990/000409 1989-01-23 1990-01-23 Method for removing dna from protein preparations WO1990008159A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30099789A 1989-01-23 1989-01-23
US300,997 1989-01-23

Publications (1)

Publication Number Publication Date
WO1990008159A1 true WO1990008159A1 (en) 1990-07-26

Family

ID=23161487

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1990/000409 WO1990008159A1 (en) 1989-01-23 1990-01-23 Method for removing dna from protein preparations

Country Status (2)

Country Link
AU (1) AU5040590A (en)
WO (1) WO1990008159A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US6914137B2 (en) 1997-12-06 2005-07-05 Dna Research Innovations Limited Isolation of nucleic acids
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US20150065689A1 (en) * 2012-04-10 2015-03-05 Dr. Reddy's Laboratories Limited Single step fractionation method
WO2019063849A1 (en) * 2017-12-20 2019-04-04 Dsm Ip Assets B.V. Purification of a polypeptide of interest

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8801098D0 (en) * 1988-03-24 1988-03-24 Pharmacia Ab APPARATUS AND METHOD FOR AUTOMATIC EXTRACTION OF EXTRA-CHROMOSOMAL DNA FROM A CELL SUSPENSION IN A CONTAINER

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4330464A (en) * 1981-07-09 1982-05-18 George Weston Limited Isolation of microbial protein with reduced nucleic acid content
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US4591564A (en) * 1982-11-10 1986-05-27 The University Of Montana Transferase enzymes which modify the 3'-termini of ribonucleic acid and methods
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452734A (en) * 1980-02-11 1984-06-05 Merck & Co., Inc. Herpes subunit vaccine
US4330464A (en) * 1981-07-09 1982-05-18 George Weston Limited Isolation of microbial protein with reduced nucleic acid content
US4591564A (en) * 1982-11-10 1986-05-27 The University Of Montana Transferase enzymes which modify the 3'-termini of ribonucleic acid and methods
US4757134A (en) * 1982-12-02 1988-07-12 The Rockefeller University IgA binding protein

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274348B1 (en) 1992-05-19 2001-08-14 Xoma Corporation Methods for the preparation of positively charged proteins
US8691969B2 (en) 1994-12-12 2014-04-08 Life Technologies As Isolation of nucleic acid
US6914137B2 (en) 1997-12-06 2005-07-05 Dna Research Innovations Limited Isolation of nucleic acids
US20150065689A1 (en) * 2012-04-10 2015-03-05 Dr. Reddy's Laboratories Limited Single step fractionation method
WO2019063849A1 (en) * 2017-12-20 2019-04-04 Dsm Ip Assets B.V. Purification of a polypeptide of interest

Also Published As

Publication number Publication date
AU5040590A (en) 1990-08-13

Similar Documents

Publication Publication Date Title
Temple et al. Comparison of ELISA and plaque-forming cell assays for measuring the humoral immune response to SRBC in rats and mice treated with benzo [a] pyrene or cyclophosphamide
Weber et al. Stoichiometry of cAMP binding and limited proteolysis of protein kinase regulatory subunits RI and R II
Rimerman et al. Phosphate-induced protein chromatography
Cavard et al. Purification and molecular properties of a new colicin
CN1199419A (en) Method for purifying viruses by chromatography
Mulchahey et al. Antibodies to the binding site of the receptor for luteinizing hormone-releasing hormone (LHRH): generation with a synthetic decapeptide encoded by an RNA complementary to LHRH mRNA.
DE68929545T2 (en) Pollen allergens
Chader et al. Steroid-Protein Interactions: XVI. Isolation and Characterization of the Corticosteroid-Binding Globulin of The Rabbit
Falkenberg et al. Localization of the binding site for streptococcal protein G on human serum albumin. Identification of a 5.5-kilodalton protein G binding albumin fragment
Chen et al. Avian tumor virus proteins and RNA in uninfected chicken embryo cells
WO1990008159A1 (en) Method for removing dna from protein preparations
US20090221040A1 (en) Antibodies active against a fusion polypeptide comprising a histidine portion
Klinman et al. The role of antibody bivalence in the neutralization of bacteriophage
US6432633B1 (en) Immunoassay method of HIV-1p24 antigen and reagent therefor
Lennox et al. A search for biosynthetic subunits of light and heavy chains of immunoglobulins
AU619177B2 (en) Receptor of the small rhinovirus receptor group
Roisin et al. Enkephalins are associated with adrenergic granules in bovine adrenal medulla
US5304636A (en) Receptor for the human rhinovirus minor group
Deppert et al. Cell surface location of simian virus 40-specific proteins on HeLa cells infected with adenovirus type 2-simian virus 40 hybrid viruses Ad2+ ND1 and Ad2+ ND2
Löw et al. Affinity labeling of GTP-binding proteins in cellular extracts
Kincaid [57] Preparation, characterization, and properties of affinity-purified antibodies to calmodulin-dependent cyclic nucleotide phosphodiesterase and the protein phosphatase calcineurin
Markel et al. Structure, function, and antigenicity of cholera toxin
Precious et al. Preliminary characterization of the urease and a 96 kDa surface-expressed polypeptide of Ureaplasma urealyticum
Gerlach et al. Purification and characterization of Streptococcus pyogenes erythrogenic toxin type A produced by a cloned gene in Streptococcus sanguis
Reichlin The distribution of specificity in rabbit antisera directed toward human hemoglobins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE